AZD 1222 — Competitive Intelligence Brief

AZD 1222 (AZD 1222) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Viral vector vaccine. Area: Immunology / Infectious Disease.

phase 3 Viral vector vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease Small molecule

Target snapshot

AZD 1222 (AZD 1222) — University Medicine Greifswald. AZD1222 is a viral vector vaccine that delivers genetic instructions for the SARS-CoV-2 spike protein to stimulate immune responses against COVID-19.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AZD 1222 TARGET	AZD 1222	University Medicine Greifswald	phase 3	Viral vector vaccine	SARS-CoV-2 spike protein
Comirnaty Original/Omicron BA.1	Comirnaty Original/Omicron BA.1	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
mRNA-1273 vaccine	mRNA-1273 vaccine	University Health Network, Toronto	marketed	mRNA vaccine	SARS-CoV-2 spike protein
Spikevax Omicron XBB.1.5	Spikevax Omicron XBB.1.5	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (XBB.1.5 variant)
Regeneron Casirivimab + Imdevimab	Regeneron Casirivimab + Imdevimab	Erin McCreary	marketed	Monoclonal antibody combination (neutralizing antibodies)	SARS-CoV-2 spike protein
COMIRNATY - BioNTech Manufacturing GmbH	COMIRNATY - BioNTech Manufacturing GmbH	Jens D Lundgren, MD	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
Comirnaty Omicron XBB.1.5	Comirnaty Omicron XBB.1.5	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (XBB.1.5 variant)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Viral vector vaccine class)

1. Janssen Vaccines & Prevention B.V. · 5 drugs in this class
2. University of Oxford · 3 drugs in this class
3. Crucell Holland BV · 3 drugs in this class
4. National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
5. Bharat Biotech International Limited · 2 drugs in this class
6. Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · 1 drug in this class
7. London School of Hygiene and Tropical Medicine · 1 drug in this class
8. Samia Hassan El-Shishtawy · 1 drug in this class
9. University Medicine Greifswald · 1 drug in this class
10. Aeras · 1 drug in this class